Novavax Offering Raises $82M for Flu Pandemic, RSV Efforts
By Randy Osborne
Tuesday, September 24, 2013
With a public offering expected to close later this week that will net the company about $82.6 million for use across its pipeline, Novavax Inc. is moving ahead to finalize cost and timeline details for the next round of trials with its U.S. government-backed quadrivalent seasonal and pandemic influenza vaccines.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.